Article
4 min read

What the New ESR1 Approvals Change About When Breast Cancer Therapy Switches

Written by
María I. Báez Ávila
Published on
November 17, 2026

In hormone receptor-positive, HER2-negative advanced breast cancer, an aromatase inhibitor paired with a CDK4/6 inhibitor remains standard first-line therapy, and acquired ESR1 mutations are among the most common reasons it stops working. The mutation develops in roughly 40% of patients on that regimen and is associated with shorter progression-free survival. Two approvals in 2026 address that population, at different points in the sequence.

Vepdegestrant (Veppanu), approved May 1, is the first FDA-approved PROTAC, recruiting the ubiquitin-proteasome system to degrade the estrogen receptor rather than block it. In VERITAC-2, among the 270 of 624 patients carrying an ESR1 mutation, median PFS was 5.0 months versus 2.1 with fulvestrant (HR 0.57; 95% CI, 0.42 to 0.77; P < .001). Overall survival is immature. The comparator matters here: fulvestrant in the post-CDK4/6 setting is a modest benchmark, and the absolute gain is 2.9 months in a heavily pretreated group.

Camizestrant (Etcamah), granted accelerated approval September 4 in combination with abemaciclib, palbociclib or ribociclib, changes the timing rather than the line. Patients must have received at least six months of aromatase inhibitor plus CDK4/6 inhibitor therapy, with ctDNA testing by an FDA-authorized assay every three months until an ESR1 mutation is detected. In SERENA-6, 3,256 patients were monitored, and the 315 with an emergent mutation and no radiographic progression were randomized to switch the aromatase inhibitor to camizestrant or continue it, with the same CDK4/6 inhibitor maintained in both arms. Median PFS was 16.0 versus 9.2 months (HR 0.44; P < .00001).

Three caveats belong with that result. The control arm continued therapy already known, molecularly, to be failing, so the trial compares switching early against waiting rather than one agent against another. Overall survival is immature, which is why the approval is accelerated and why the finding is delayed progression rather than survival benefit. And 315 actionable findings from 3,256 patients monitored means nine of ten are tested serially without a result that changes anything. Cost-effectiveness analyses have not been published.

Both drugs carry cardiac requirements. Vepdegestrant calls for correcting hypokalemia and hypomagnesemia, a baseline ECG, no initiation above a QTc of 470 msec, and a repeat ECG at approximately four weeks. Camizestrant carries a boxed warning for arrhythmia risk with concomitant QTc-prolonging drugs, with ECG at baseline, weekly for the first two weeks, then periodically. Ribociclib both prolongs QTc and is a strong CYP3A inhibitor, so in a regimen where the CDK4/6 inhibitor continues unchanged by design, the choice of partner agent becomes a safety decision.

Clinical takeaway: the question is shifting from what comes next to when that decision gets made, and the answer now depends on a test result rather than an image. Confirm which ESR1 assay is available locally and what its turnaround is before committing to a three-month cadence, since available assays differ in sensitivity and mutation coverage, serial testing is not routinely reimbursed, and a cadence that cannot be met reliably produces late switches rather than early ones. Screen the full medication list for QTc-prolonging agents before initiating either drug, and treat a ribociclib-containing regimen as the one needing the closest cardiac follow-up. And set expectations carefully: the evidence to date shows longer time to progression, not longer survival.

‍

Share this post
Get Updates

The pharmacy benefit story moves fast. Keep the whole picture in view.

The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.

Colleagues discussing documents in a conference room
Bring Us Your Data

See the whole pharmacy picture.

Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.